# Safety, Tolerability and Immunogenicity of an Trivalent Inactivated Cell-Culture Influenza Vaccine in Healthy Adults

> **NCT03893669** · PHASE1 · COMPLETED · sponsor: **SK Chemicals Co., Ltd.** · enrollment: 100 (actual)

## Conditions studied

- Prevention of Influenza

## Interventions

- **BIOLOGICAL:** NBP607
- **BIOLOGICAL:** Agrippal

## Key facts

- **NCT ID:** NCT03893669
- **Lead sponsor:** SK Chemicals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2012-10
- **Final completion:** 2012-11
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2019-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03893669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03893669, "Safety, Tolerability and Immunogenicity of an Trivalent Inactivated Cell-Culture Influenza Vaccine in Healthy Adults". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03893669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*